To get in touch with XenTech, simply fill out the form below.
Subscribe to Supplier
XenTech to showcase Mouse Trials at AACR
Evry, France: – Biotech and contract research organisaton XenTech is to bring significant results from its recent preclinical oncological research to the world’s leading cancer conference later this month.
The prestigious American Association for Cancer Research (AACR) Annual Meeting is one of the highlights of the year for oncology researchers. The 2015 meeting is a five-day event opening April 18 that is expecting more than 17,000 participants from 60 countries. The accompanying exhibitions will feature some 350 organizations from around the world.
Mouse Trials Demo
XenTech is expert in evaluating cancer drug efficacy and identifying biomarkers and therapeutic targets through gene sequencing. The company has attended every AACR annual meeting since 2006 and this year will be exhibiting its preclinical efficacy services for the pharmaceutical industry at Booth 357.
“For us, AACR’s annual conference is the year’s leading ‘place-to-be’ meeting covering the full spectrum of cancer research,” said Dr. Jean-Gabriel Judde, XenTech President and Chief Scientific Officer, who will be leading the company’s team in Philadelphia.
The XenTech stand will be able to demonstrate its latest service offering: Mouse Trials, a new system for hosting Preclinical Phase 2 equivalent trials in patient-derived tumor xenograft (PDX) panels (service for realizing Preclinical trials in patient-derived tumor xenograft (PDX) panels.)
“We believe the Mouse Trials concept will be of great interest to all those research organizations (biotech companies) seeking to Improve R&D productivity during early drug development stages by finding new ways to validate the therapeutic efficacy of their technology,” said Dr. Judde.
Collaborative research projects
XenTech will also present two posters to the meeting. The first arises from its partnership with Miltenyi Biotec to develop sialyl-glycolipid SSEA4 to mark a subpopulation of chemotherapy-resistant breast cancer cells with mesenchymal features.
XenTech will also post a report on its partnership with AstraZeneca to research use of the MET inhibitor AZD6094 (also called Savolitinib or HMPL-504) to induce regression in papillary renal cell carcinoma patient derived xenograft models.
XenTech will be offering new partnership projects at AACR and Dr. Judde’s presence in Philadelphia provides unique opportunities for collaborators and potential partners to address scientific questions at high level and to acquire strategic insights.
XenTech is inviting AACR delegates who wish to confer with Dr. Judde to contact the company in advance of the event to set up meetings.
XenTech is an innovative biotech/CRO company specializing in the preclinical evaluation of cancer drug efficacy and the identification of biomarkers and therapeutic targets. It offers a unique collection of patient-derived tumor xenografts (PDX). PDX closely match biological features of patient tumors for each aspect of phenotypic characteristics including histology, gene expression, genomics and drug response.
XenTech has assembled one of the world’s most impressive collections of PDX models that are extensively characterized and associated to molecular data, including gene expression, copy number data, and manually curated mutations. Its preclinical platform is of considerable value for translational research in oncology, notably for pharmacology and identification of drug response markers for personalized medicine. XenTech participates in the development of novel cancer therapies by offering its PDX-based services, tumor models and expertise in preclinical oncology to stakeholders in oncology research. XenTech also develops internal oncology biomarker programs to correlate drug response with molecular features of tumors.
XenTech is known worldwide for its renowned oncology translational platform, its unique panel of patient-derived breast cancer xenografts and its extremely experienced scientific team.
About AACR 2015
The Annual Meeting of the American Association for Cancer Research is one of the world’s largest and most prestigious life sciences events.
AACR 2015 will be held at the Pennsylvania Convention Center in the Association’s home city of Philadelphia from April 18 to April 22. This year’s AACR meeting has adopted the theme of “Bringing Cancer Discoveries to Patients” to emphasize the essential links between discovery and treatment and it reinforcing the vital role of research in underpinning all progress toward cancer cures.
The exhibition (open from April 19) features more than 350 companies and organizations representing a wide array of products and services in laboratory and clinical research. More than 6,000 scientific papers will be presented over the five days of the meeting.
Last year’s AACR Meeting, held in San Diego, California, attracted more than 17,000 visitors and delegates from around the world.